Corticosteroids and Thrombotic Risk in Immune Thrombocytopenia: A Systematic Review and Meta-Analysis
Hemato · 02.11.2026 · 7 (4) · 40
DOI: 10.3390/hemato7040040 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Hemato, online erschienen am 02.11.2026. Verfasst von Dragoș-Claudiu Popescu und 8 weiteren Autor:innen. Die Arbeit nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: Corticosteroids are the standard first-line treatment for immune thrombocytopenia (ITP), a disorder that itself carries an excess risk of thrombosis, yet the evidence on corticosteroid-associated thrombotic risk in ITP has not been systematically synthesized. We aimed to estimate the association between corticosteroid exposure and venous (VT) and arterial thrombosis (AT) in ITP.
Methods
Following PRISMA 2020 (PROSPERO CRD420261504746), we searched PubMed/MEDLINE, Scopus, Cochrane CENTRAL, LILACS, ClinicalTrials.gov, and WHO ICTRP from 2000 to 28 September 2026. Adjusted hazard ratios (HRs) were synthesized by study and outcome; crude odds ratios (ORs) were pooled with random-effects (REML) models within two subgroups (European cohorts; Asian hospital-based series). Risk of bias was assessed with JBI tools (and ROBINS-E for the adjusted cohorts) and certainty of evidence with GRADE.
Results
Twelve studies (18,059 participants) were included, ten in the meta-analysis. Adjusted evidence came almost entirely from a French nationwide cohort (10,039 adults), in which time-varying corticosteroid exposure was associated with VT (HR 3.55, 95% CI 2.74–4.58; approximately 11 additional hospitalizations per 1000 person-years of exposure) but not with AT (HR 1.15, 0.94–1.41); an Italian cohort with ever-use exposure gave imprecise estimates (VT 2.2, 0.5–10.4; AT 5.3, 0.9–40.6). Crude ORs were 3.48 (1.73–7.01) in two European cohorts and 0.82 (0.59–1.14) in seven Asian hospital-based series, none of which adjusted for corticosteroid exposure (P for subgroup difference < 0.001). Two randomized trials comparing corticosteroid regimens reported no thrombotic events (0/328; exact 95% CI 0–1.1%). Certainty was low for VT and very low for the other outcomes.
Conclusions
Low-certainty evidence, dominated by a single nationwide cohort, suggests that current corticosteroid exposure is associated with an approximately 3.5-fold higher hazard of VT in adults with ITP, without a consistent arterial association. Retrospective series that compare prior use without a defined exposure window may be less informative about the risk associated with current exposure. Corticosteroid exposure may reasonably be considered in VT risk assessment in ITP.
Zitieren
APA
Popescu, D., Găman, M., Truican, R., Olărașu, C., Diaconescu, D., Ciufu, C., Irimia, R. M., Bumbea, H., & Soare, D. (2026). Corticosteroids and Thrombotic Risk in Immune Thrombocytopenia: A Systematic Review and Meta-Analysis. Hemato, 7(4), 40. https://doi.org/10.3390/hemato7040040
Vancouver
Popescu D, Găman M, Truican R, Olărașu C, Diaconescu D, Ciufu C, et al. Corticosteroids and Thrombotic Risk in Immune Thrombocytopenia: A Systematic Review and Meta-Analysis. Hemato. 2026;7(4):40. doi:10.3390/hemato7040040
BibTeX
@article{Popescu2026,
author = {Popescu, Dragoș-Claudiu and Găman, Mihnea-Alexandru and Truican, Raluca and Olărașu, Cătălina and Diaconescu, Daniela and Ciufu, Cristina-Maria and Irimia, Ruxandra Maria and Bumbea, Horia and Soare, Delia},
title = {Corticosteroids and Thrombotic Risk in Immune Thrombocytopenia: A Systematic Review and Meta-Analysis},
journal = {Hemato},
year = {2026},
volume = {7},
number = {4},
pages = {40},
doi = {10.3390/hemato7040040}
}
EUVIMED